Literatur
-
1
Fischbach W, Malfertheiner P, Hoffmann J C et al.
S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit” der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) in Zusammenarbeit mit der Deutschen Gesellschaft für Hygiene und Mikrobiologie, Gesellschaft für Pädiatrische Gastroenterologie und Ernährung e. V. und der Deutschen Gesellschaft für Rheumatologie – AWMF-Register-Nr. 021 / 001.
Z Gastroenterol.
2009;
47
68-102
-
2
Bhatt D L, Scheiman J, Abraham N S et al.
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
Circulation.
2008;
118
1894-1909
-
3
Kushner F G, Hand M, Smith S C et al.
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Circulation.
published online Nov 18, 2009
DOI: 10.1161 /CIRCULATIONAHA.109.192663
-
4 US Food and Drug Administration .Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix). May/2009 http://http:www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety/ucm079520.htm
-
5 European Medicines Agency .Public statement on possible interaction between clopidogrel and proton pump inhibitors. May/2009 http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf
-
6 US Food and Drug Administration .Public Health Advisory: Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC). http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm190825.htm
-
7
The Clopidogrel in Unstable Angina tp Prevent Recurrent Events Trial Investigators .
Effects of Clopidogrel to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation.
NEJM.
2001;
345 (7)
494-502
-
8
Sabatine M S, Cannon C P, Gibson C M et al.
Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation.
NEJM.
2005;
352 (12)
1179-1189
-
9
Matetzky S, Shenkman B, Guetta V et al.
Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction.
Circulation.
2004;
109
3171-3175
-
10
Wiviott S D, Antman E M.
Clopidogrel Resistance. A New Chapter in a Fast-Moving Story.
Circulation.
2004;
109
3064-3067
-
11
Wiviott S D, Braunwald E, McCabe C H et al.
Triton-TIMI-38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes.
N Engl J Med.
2007;
357 (20)
2001-2015
-
12 CURRENT-OASIS-7-Studie. Vorgestellt auf dem Kongress der europäischen Gesellschaft für Kardiologie. Barcelona; 2009
-
13
Conolly S J, Pogue J, Hart R G ACTIVE Investigators et al..
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
New Engl J Med.
2009;
360 (20)
2066-2078
-
14
Antithrombotic Trialists`(ATT) Collaboration .
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials.
Lancet.
2009;
373
1849-1860
-
15
CAPRIE Steering Committee .
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet.
1996;
348
1329-1339
-
16
Serebruany V L, Malinin A I, Ferguson J J et al.
Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comparing 129 314 patients.
Fundamental Clin Pharmacol.
2008;
22
315-321
-
17
Connolly S J, Ezekowitz M D, Yusuf S et al.
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
N Engl J Med.
2009;
361
1139-1151
-
18
Hart R G, Benavente O, McBride R et al.
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis.
Ann Intern Med.
1999;
131
492-501
-
19
The Active Investigators. Writing Group .
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation.
N Engl J Med.
2009;
360
2066-2078
-
20
Yeomans N, Lanas A, Labenz J et al.
Efficacy of Esomeprazole (20 mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin.
Am J Gastroenterol.
2008;
103
1-9
-
21
Scheiman J M, Rendsburg C J, Uebel van P et al.
Prevention of low-dose acetylsalicyl acid-associated gastric/duodenal ulcers with esomeprazole 20 mg and 40 mg once daily in patients at increased risk of ulcer development: A randomized controlled trial (OBERON).
Gastroenterology.
2009;
136 (Suppl)
412
-
22
Ibanez L, Vidal X, Vendrell L et al.
Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Upper gastrointestinal bleeding associated with antiplatelet drugs.
Aliment Pharmacol Ther.
2006;
23(2)
235-242
-
23 Lin K Y, Hernandez-Diaz S, Rodriguez L AG. Effect of Anti-Secretory Medicines and Nitrates on the Risk of Ulcer Bleeding Among Users of Clopidogrel, Low-Dose Acetylsalicyl Acid, Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs and Oral Anticoagulants. DDW; 2010 #665
-
24 Cuschieri J R, Drawz P, Falck-Ytter Y et al. Risk Factors for Acute GI Bleeding Following Myocardial Infarction in Patients Who Are Prescribed Clopidogrel. DDW; 2010 #108
-
25
Kazui M, Nishiya Y, Ishizuka T et al.
Identification of the human cytochrome P 450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Drug Metab Dispos.
2010;
38 (1)
92-99
-
26
Sibbing D, Koch W, Gebhard D et al.
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Circulation.
2010;
121 (4)
512-518
-
27
Li X -Q, Andersson T B, Ahlström A et al.
Comparison of inhibitory effects of the proton pump inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P 450.
Drug Metab Dispos.
2004;
32
821-827
-
28
Ko J W, Sukhova N, Thacker D et al.
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P 450 isoforms.
Drug Metab Dispos.
1997;
25 (7)
853-862
-
29
Lefebvre R A, Flouvat B, Karolac-Tamisier S et al.
Influence of lansoprazole treatment on diazepam plasma concentrations.
Clin Pharmacol Ther.
1992;
52 (5)
458-463
-
30
Gilard M, Arnaud B, Cornily J C et al.
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
J Am Coll Cardiol.
2008;
51
256-260
-
31
Cuisset T, Frere C, Quirlici J et al.
Comparison of omeprazole and pantoprazole influence on a high 150 mg clopidogrel maintenance dose. The PACA (Proton Pump Inhibitors And clopidogrel Association) prospective randomized study.
J Am Coll Cardiol.
2009;
54 (13)
1149-1153
-
32
O’Donoghue M L, Braunwald E, Antman E M et al.
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
Lancet.
2009;
374
989-997
-
33
Price M J, Nayak K R, Barker C M et al.
Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Am J Cardiol.
2009;
103
1339-1343
-
34
Zuern C S, Geisler T, Lutilsky N et al.
Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy.
Thromb Res.
2010;
125
e51-e54
-
35
Sibbing D, Morath T, Stegherr J et al.
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Thromb Haemost.
2009;
101
714-719
-
36
Siller-Matula J M, Spiel A O, Lang I M et al.
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.
Am Heart J.
2009;
157
148.e1-148.e5
-
37 FDA .Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). (17. 11. 2009) http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm
-
38
Beitelshees A L, McLeod H L.
Clopidogrel pharmacogenetics: promising steps towards patient care?.
Arterioscler Thromb Vasc Biol.
2006;
26
1681-1683
-
39
Ho P M, Maddox T M, Wang L et al.
Risk of Adverse Outcomes associated with concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrom.
JAMA.
2009;
301 (9)
937-944
-
40 Van Boxel O S, Oijen M G, Hagenaars M P et al. New Clopidogrel Users on PPIs Are At an Increased Risk of Cardiovascular and Gastrointestinal Complications – Results of a Large Dutch Cohort Study. DDW; 2010 #107
-
41
Juurlink D N, Gomes van T, Ko D T et al.
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
CMAJ.
2009;
180 (7)
713-718
-
42
Stockl K M, Zakharyan A, Harada A S et al.
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.
Arch Intern Med.
2010;
170 (8)
704-710
-
43
Gaglia M A, Torguson R, Hanna N et al.
Relation of proton pump inhibitor use after percutaneous intervention with drug-diluting stents to outcomes.
Am J Cardiol.
2010;
105 (6)
833-838
-
44
Ray W A, Murray K T, Griffin M R et al.
Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.
Ann Intern Med.
2010;
152 (6)
337-345
-
45
Kwok C S, Loke Y K.
Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortalitiy in patients receiving clopidogrel.
Aliment Pharmacol Ther.
2010;
31
810-823
-
46 Ngamruengphong S, Leontiadis G I, Crowell M D et al. Risk of Adverse Cardiovascular Events With Concomitant Use of Clopidogrel and Proton Pump Inhibitors (PPI): Systematic Review and Meta-Analysis of Observational Studies. DDW; 2010 # T1078
-
47 Gerson L B, McMahon D, Olkin I et al. Meta-Analysis of Interaction Between Clopidogrel and Proton Pump Inhibitor Therapy. DDW; 2010 # W1108
-
48
Dunn S P, Macaulay T E, Brennan D M et al.
Abstract 3999: Baseline Proton Pump Inhibitor Us is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial.
Circulation.
2008;
118
S815
-
49
Simon T, Verstuyft C, Mary-Krause M et al.
Genetic determinants of response to clopidogrel and cardiovascular events.
N Engl J Med.
2009;
360
363-375
-
50
Zairis M, Patsourakos N, Makrygiannis S et al.
The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting.
Eur Heart J.
2008;
29 (Suppl)
134
-
51
Depta J P, Bhatt D L.
Omeprazole and clopidogrel: Should clinicians be worried?.
Cleve Clin J Med.
2010;
77 (2)
113-116
-
52
Targownik L E, Metge C J, Leung S et al.
The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Gastroenterology.
2008;
134 (4)
937-944
-
53
Kenngott S, Olze R, Kollmer M et al.
Clopidogrel and Proton Pump Inhibitor (PPI) Interaction: Separate Intake and a Non-omeprazole PPI the Solution?.
Eur J Med Res.
2010;
15
1-5
-
54
Neubauer H, Engelhardt A, Krüger J C et al.
Pantoprazole does not influence the antiplatelet effect of Clopidogrel – A whole blood aggregometry study following coronary stenting.
J Cardiovasc Pharmacol.
2010;
;April 17 Epub ahead of print
-
55 Hokimoto S, Ogawa H. Is It Safe to Use a Proton Pump Inhibitor With Clopidogrel? A Comparison of Clopidogrel With or Without Rabeprazole in Japan. DDW; 2010 # T 1145
-
56 Furuta T, Sugimoto M, Kodaira C et al. Effect of Different Proton Pump Inhibitors on the Antiplatelet Activity of Clopidogrel in Relation to CYP2C19 Genotype Status. DDW; 2010 # T 1013
Prof. Dr. Wolfgang Fischbach
Medizinische Klinik II und Klinik für Palliativmedizin, Klinikum Aschaffenburg, Akademisches Lehrkrankenhaus der Universität Würzbug
Am Hasenkopf
63739 Aschaffenburg
Phone: ++ 49/60 21/32 30 10
Fax: ++ 49/60 21/32 30 31
Email: med2-aschaffenburg@t-online.de
